Dual specificity phosphatase 6 (DUSP6) is an ETS-regulated negative feedback mediator of oncogenic ERK signaling in lung cancer cells

Carcinogenesis

Volumn 31, Issue 4, 2010, Pages 577-586

  Zhang, Zhenfeng ^a   Kobayashi, Susumu ^b   Borczuk, Alain C ^c   Leidner, Rom S ^a   LaFramboise, Thomas ^a   Levine, Alan D ^a   Halmos, Balazs ^a,c  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c NewYork Presbyterian Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; DUAL SPECIFICITY PHOSPHATASE 6; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; MITOGEN ACTIVATED PROTEIN KINASE; N [4 (3 BROMOANILINO) 6 QUINAZOLINYL] 2 BUTYNAMIDE; SMALL INTERFERING RNA; DUSP6 PROTEIN, HUMAN; ETS1 PROTEIN, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE KINASE; TRANSCRIPTION FACTOR ETS 1;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REGULATION; ENZYME SPECIFICITY; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; NEGATIVE FEEDBACK; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; DRUG ANTAGONISM; FEEDBACK SYSTEM; GENETICS; LUNG TUMOR; METABOLISM; PHYSIOLOGY; TUMOR CELL LINE;

APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; DUAL SPECIFICITY PHOSPHATASE 6; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEEDBACK, PHYSIOLOGICAL; HUMANS; LUNG NEOPLASMS; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; PROTO-ONCOGENE PROTEIN C-ETS-1; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA, SMALL INTERFERING;

EID: 77950877457     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgq020     Document Type: Article

References (47)

1. Jemal, A. et al. (2008) Cancer statistics, 2008. CA Cancer J. Clin., 58, 71-96.
2. Jemal, A. et al. (2008) Annual report to the nation on the status of cancer, 1975-2005, featuring trends in lung cancer, tobacco use, and tobacco control. J. Natl Cancer Inst., 100, 1672-1694.
3. Dhillon, A.S. et al. (2007) MAP kinase signalling pathways in cancer. Oncogene, 26, 3279-3290.
4. Shepherd, F.A. et al. (2005) Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med., 353, 123-132.
5. Ciardiello, F. et al. (2008) EGFR antagonists in cancer treatment. N. Engl. J. Med., 358, 1160-1174.
6. Lynch, T.J. et al. (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med., 350, 2129-2139.
7. Paez, J.G. et al. (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science, 304, 1497-1500.
8. Pao, W. et al. (2004) EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl Acad. Sci. USA, 101, 13306-13311.
9. Kumar, A. et al. (2008) Structure and clinical relevance of the epidermal growth factor receptor in human cancer. J. Clin. Oncol., 26, 1742-1751.
10. Pao, W. et al. (2005) KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med., 2, e17.
11. Jeffrey, K.L. et al. (2007) Targeting dual-specificity phosphatases: manipulating MAP kinase signalling and immune responses. Nat. Rev. Drug Discov., 6, 391-403.
12. Pao, W. et al. (2005) Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med., 2, e73.
13. Kobayashi, S. et al. (2005) EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N. Engl. J. Med., 352, 786-792.
14. Yu, Z. et al. (2007) Resistance to an irreversible epidermal growth factor receptor (EGFR) inhibitor in EGFR-mutant lung cancer reveals novel treatment strategies. Cancer Res., 67, 10417-10427.
15. Kobayashi, S. et al. (2005) An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor. Cancer Res., 65, 7096-7101.
16. Kwak, E.L. et al. (2005) Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc. Natl Acad. Sci. USA, 102, 7665-7670.
17. Kobayashi, S. et al. (2006) Transcriptional profiling identifies cyclin D1 as a critical downstream effector of mutant epidermal growth factor receptor signaling. Cancer Res., 66, 11389-11398.
18. Patterson, K.I. et al. (2009) Dual-specificity phosphatases: critical regulators with diverse cellular targets. Biochem. J., 418, 475-489.
19. Keyse, S.M. (2008) Dual-specificity MAP kinase phosphatases (MKPs) and cancer. Cancer Metastasis Rev., 27, 253-261.
20. Echevarria, D. et al. (2005) Mkp3 is a negative feedback modulator of Fgf8 signaling in the mammalian isthmic organizer. Dev. Biol., 277, 114-128.
21. Li, C. et al. (2007) Dusp6 (Mkp3) is a negative feedback regulator of FGFstimulated ERK signaling during mouse development. Development, 134, 167-176.
22. Maillet, M. et al. (2008) DUSP6 (MKP3) null mice show enhanced ERK1/2 phosphorylation at baseline and increased myocyte proliferation in the heart affecting disease susceptibility. J. Biol. Chem., 283, 31246-31255.
23. Ekerot, M. et al. (2008) Negative-feedback regulation of FGF signalling by DUSP6/MKP-3 is driven by ERK1/2 and mediated by Ets factor binding to a conserved site within the DUSP6/MKP-3 gene promoter. Biochem. J., 412, 287-298.
24. Jurek, A. et al. (2009) Negative and positive regulation of MAP kinase phosphatase 3 controls PDGF-induced Erk activation. J. Biol. Chem, 284, 4626-4634.
25. Furukawa, T. et al. (1998) Genomic analysis of DUSP6, a dual specificity MAP kinase phosphatase, in pancreatic cancer. Cytogenet. Cell Genet., 82, 156-159.
26. Muda, M. et al. (1996) MKP-3, a novel cytosolic protein-tyrosine phosphatase that exemplifies a new class of mitogen-activated protein kinase phosphatase. J. Biol. Chem., 271, 4319-4326.
27. Muda, M. et al. (1998) The mitogen-activated protein kinase phosphatase-3 N-terminal noncatalytic region is responsible for tight substrate binding and enzymatic specificity. J. Biol. Chem., 273, 9323-9329.
28. Chan, D.W. et al. (2008) Loss of MKP3 mediated by oxidative stress enhances tumorigenicity and chemoresistance of ovarian cancer cells. Carcinogenesis, 29, 1742-1750.
29. Huang, G. et al. (2008) 15-Hydroxyprostaglandin dehydrogenase is a target of hepatocyte nuclear factor 3beta and a tumor suppressor in lung cancer. Cancer Res., 68, 5040-5048.
30. Zhou, B. et al. (2006) Mapping ERK2-MKP3 binding interfaces by hydrogen/deuterium exchange mass spectrometry. J. Biol. Chem., 281, 38834-38844.
31. Wishart, M.J. et al. (1995) A single mutation converts a novel phosphotyrosine binding domain into a dual-specificity phosphatase. J. Biol. Chem., 270, 26782-26785.
32. Dowd, S. et al. (1998) Isolation of the human genes encoding the pyst1 and Pyst2 phosphatases: characterisation of Pyst2 as a cytosolic dual-specificity MAP kinase phosphatase and its catalytic activation by both MAP and SAP kinases. J. Cell Sci., 111(Pt 22), 3389-3399.
33. Myers, E. et al. (2005) Associations and interactions between Ets-1 and Ets-2 and coregulatory proteins, SRC-1, AIB1, and NCoR in breast cancer. Clin. Cancer Res., 11, 2111-2122.
34. Farooq, A. et al. (2004) Structure and regulation of MAPK phosphatases. Cell. Signal., 16, 769-779.
35. Wu, J.J. et al. (2005) The noncatalytic amino terminus of mitogen-activated protein kinase phosphatase 1 directs nuclear targeting and serum response element transcriptional regulation. Mol. Cell. Biol., 25, 4792-4803.
36. Masuda, K. et al. (2001) MKP-7, a novel mitogen-activated protein kinase phosphatase, functions as a shuttle protein. J. Biol. Chem., 276, 39002-39011.
37. Bettini, M.L. et al. (2007) MAP kinase phosphatase activity sets the threshold for thymocyte positive selection. Proc. Natl Acad. Sci. USA, 104, 16257-16262. 586
38. Okudela, K. et al. (2009) Down-regulation of DUSP6 expression in lung cancer: its mechanism and potential role in carcinogenesis. Am. J. Pathol., 175, 867-881.
39. Xu, S. et al. (2005) Abrogation of DUSP6 by hypermethylation in human pancreatic cancer. J. Hum. Genet., 50, 159-167.
40. Bloethner, S. et al. (2005) Effect of common BRAF and N-RAS mutations on global gene expression in melanoma cell lines. Carcinogenesis, 26, 1224-1232.
41. Bermudez, O. et al. (2008) Post-translational regulation of the ERK phosphatase DUSP6/MKP3 by the mTOR pathway. Oncogene, 27, 3685- 3691.
42. Furukawa, T. et al. (2008) Feedback regulation of DUSP6 transcription responding to MAPK1 via ETS2 in human cells. Biochem. Biophys. Res. Commun., 377, 317-320.
43. Hakansson, P. et al. (2008) Gene expression analysis of BCR/ABL1dependent transcriptional response reveals enrichment for genes involved in negative feedback regulation. Genes Chromosomes Cancer, 47, 267-275.
44. Ramnarain, D.B. et al. (2006) Differential gene expression analysis reveals generation of an autocrine loop by a mutant epidermal growth factor receptor in glioma cells. Cancer Res., 66, 867-874.
45. Warmka, J.K. et al. (2004) Mitogen-activated protein kinase phosphatase-3 is a tumor promoter target in initiated cells that express oncogenic Ras. J. Biol. Chem., 279, 33085-33092.
46. Marchetti, S. et al. (2004) Inducible expression of a MAP kinase phosphatase3-GFP chimera specifically blunts fibroblast growth and ras-dependent tumor formation in nude mice. J. Cell. Physiol., 199, 441-450.
47. Chen, H.Y. et al. (2007) A five-gene signature and clinical outcome in nonsmall-cell lung cancer. N. Engl. J. Med., 356, 11-20.